

Rationale and protocol for a safety, tolerability and feasibility randomized, parallel group, double-blind, placebo-controlled, pilot study of a novel ketone ester targeting frailty via immunometabolic geroscience mechanisms.

Brianna. J Stubbs¹, Gabriela Alvarez-Azanedo¹, Sawyer Peralta¹, Stephanie Roa-Diaz¹, Wyatt Gray¹, Laura Alexander¹, Wendie Silverman-Martin¹, Thelma Garcia¹, Traci M. Blonquist², Vaibhav Upadhyay^{3,7}, Peter J. Turnbaugh^{3,4}, James B. Johnson⁵, John C. Newman^{1,6}

¹ Buck Institute for Research on Aging, Novato, CA, USA

² Biofortis, Mérieux NutriSciences, Addison, IL, United States,

³ Department of Microbiology & Immunology, UCSF, San Francisco, CA, USA 94143

⁴ Chan Zuckerberg Biohub-San Francisco, San Francisco, CA, USA 94158

⁵ Independent Researcher, Greenbrae, CA, USA.

⁶ Division of Geriatrics, UCSF, San Francisco, California, USA.

⁷ Department of Medicine, UCSF, San Francisco California, USA.

SHORT TITLE: Ketone ester safety and tolerability in older adults

* Correspondence: Dr Brianna J. Stubbs: bstubbs@buckinstitute.org ;

Dr John C. Newman jnewman@buckinstitute.org

Study Sponsor Contact:

Juniper Pennypacker, VP of Scientific Operations and Chief of Staff, Buck Institute for Research on Aging (jpennypacker@buckinstitute.org)

Clinicaltrials.gov registration number: NCT05585762

Current protocol version number and date: version 1.2, approved on 17th January 2023

1 Abbreviations

1-RM	1 Repetition Maximum
ADL	Activities of Daily Living
AEs	Adverse Events
BDO	(R)-1,3-butanediol
BH-BD	Bis-hexanoyl (R)-1,3-butanediol
BHB	Beta-hydroxybutyrate
BMI	Body Mass Index
BO-BD	Bis-octanoyl (R)-1,3-butanediol
BTQ	Beverage tolerability questionnaire
CSHA	Canadian Study of Health and Aging
CRF	Case Report Form
DSST	Digit Symbol Substitution Test
IADL	Instrumental Activities of Daily Living
ITT	Intention to treat
KEs	Ketone Esters
MoCA	Montreal Cognitive Assessment
PLA	Placebo
PP	Per protocol
QoL	Quality of Life
SASP	Senescence-associated secretory phenotype
SPPB	Short Physical Performance Battery

2

3

4 **Abstract**

5 **Background:** Frailty is a geriatric syndrome characterized by chronic inflammation and
6 metabolic insufficiency that creates vulnerability to poor outcomes with aging. We
7 hypothesize that geroscience interventions, which target mechanisms of aging, could
8 ameliorate frailty. Metabolites such as ketone bodies are candidate geroscience interventions,
9 having pleiotropic effects on inflammo-metabolic aging mechanisms. Ketone esters (KEs)
10 induce ketosis without dietary changes, but KEs have not been studied in an older adult
11 population. Our long-term goal is to examine if KEs modulate geroscience mechanisms and
12 clinical outcomes relevant to frailty in older adults.

13 **Objectives:** The primary objective of this randomized, placebo-controlled, double-blinded,
14 parallel-group, pilot trial is to determine tolerability of 12-weeks of KE ingestion in a
15 generalizable population of older adults (≥ 65 years). Secondary outcomes include safety and
16 acute blood ketone kinetics. Exploratory outcomes include physical function, cognitive
17 function, quality of life, aging biomarkers and inflammatory measures.

18 **Methods:** Community-dwelling adults who are independent in activities of daily living, with
19 no unstable acute medical conditions (n=30) will be recruited. The study intervention is a KE
20 or a taste, appearance, and calorie matched placebo beverage. Initially, acute 4-hour ketone
21 kinetics after 12.5g or 25g of KE consumption will be assessed. After collection of baseline
22 safety, functional, and biological measurements, subjects will randomly be allocated to
23 consume KE 25g or placebo once daily for 12-weeks. Questionnaires will assess tolerability
24 daily for 2-weeks, and then via phone interview at bi-monthly intervals. Safety assessments
25 will be repeated at week 4. All measures will be repeated at week 12.

26 **Conclusion:** This study will evaluate feasibility, tolerability, and safety of KE consumption
27 in older adults and provide exploratory data across a range of geroscience-related endpoints.

28 This data will inform design of larger trials to rigorously test KE effects on geroscience
29 mechanisms and clinical outcomes relevant to frailty.

30 Words Count: 297 (300 limit)

31 **Keywords:** ketones, ketone ester, ketone di-ester, exogenous ketone, beta-hydroxybutyrate,
32 frailty, safety, tolerance, geroscience

33

34 **Introduction**

35 The geroscience approach of modulating fundamental aging mechanisms holds promise
36 for generating new therapeutics for multifactorial conditions of aging which contribute to
37 functional decline, disability, and loss of independence in older adults (1, 2). Frailty syndrome
38 is one such condition, conceptualized as a state of reduced physiological reserve and increased
39 vulnerability to adverse health stresses that is a powerful risk factor for disability,
40 institutionalization, and death (3). Frailty is increasingly common with advancing age, with
41 around 15% of adults over 65 years old in the United States meeting one standard definition
42 (4). The pathophysiology of frailty is complex, multisystem, and poorly understood, but is
43 thought to include cellular energy production deficits along with chronic inflammation and
44 immune dysfunction (5, 6). These are among the molecular mechanisms often referred to as
45 “Hallmarks of Aging”, common mechanisms that change with age and underlie many diseases
46 and conditions of aging (7). Geroscience is the emerging field that seeks to manipulate these
47 mechanisms to improve human health. The Geroscience Hypothesis, yet untested in human
48 clinical trials, holds that intervening upon common underlying mechanisms of aging may
49 ameliorate or prevent a variety of both specific chronic diseases of aging as well as
50 multisystem geriatric syndromes such as frailty (1). As of yet, there are no specific molecular
51 therapies for frailty, although exercise programs, specialized geriatric care models, and
52 nutritional interventions can positively alter the frailty phenotype and mitigate its
53 consequences (8).

54 Nutrition and aging have long been intertwined through decades of study of the effects of
55 dietary restriction and fasting on aging in animal models (9) and now humans (e.g. CALERIE
56 (10), HALLO-P (NCT05424042)). A deepening understanding of the molecular mechanisms
57 involved in fasting and dietary restriction has led to small molecule interventions now under
58 investigation in clinical trials targeting various aging phenotypes, as well as a popular upswell

59 of public and scientific interest in these dietary strategies. One key shared physiological
60 element of such metabolic states is the production and utilization of ketone bodies. Ketone
61 bodies, of which the most abundant is beta-hydroxybutyrate (β HB), are small molecules
62 synthesized in the liver from lipids which circulate in the blood to provide non-glucose energy
63 to extrahepatic tissues such as muscle, brain, heart, and other organs. Ketone bodies are
64 synthesized and circulate constitutively, but are also strongly induced during fasting (11). The
65 energetic and molecular signaling activities of ketone bodies, including supporting
66 mitochondrial function and regulating inflammatory activation, support a mechanistic role in
67 modulating aging and may be directly relevant to frailty (12). We and others previously
68 showed that a ketogenic diet, a dietary method of producing ketone bodies by reducing
69 carbohydrate intake without fasting, extended healthy lifespan in wild-type mice including
70 slowing overall aging-related functional declines, murine clinical frailty scores, and muscle
71 strength declines (13, 14).

72 Ketone esters (KEs), such as bis-octanoyl-(R)1,3-butanediol, are small molecules that
73 deliver ketone bodies without other dietary changes (15, 16). KEs are hydrolyzed in the gut to
74 release ketogenic fatty acids and a ketogenic alcohol, which are then metabolized in the liver
75 to release ketone bodies (17). In preclinical models, ketone bodies and KEs attenuate muscle
76 atrophy through anticatabolic signaling activities (18, 19), improve heart function in age-
77 related heart failure through direct energetic support (20, 21), and promote healthy function of
78 T cell subpopulations (22, 23). This hypothesis is further supported by demonstrated effects of
79 KEs on blood glucose control (24-27), physical (28-30), cognitive (31-33), immune (34), and
80 cardiovascular (33, 35) function in younger adult populations. These examples support our
81 central hypothesis that ketone bodies delivered through KEs may ameliorate the frailty
82 syndrome through multi-system energetic and signaling activities that improve metabolic and
83 immune function. KEs have not been investigated in older adult populations.

84 Here we describe the protocol for a randomized, placebo-controlled, double-blinded,
85 parallel-group pilot clinical trial with the objective of generating the first human safety and
86 tolerance data for KEs in a generalizable population of older adults: The Buck Institute Ketone
87 Ester (BIKE) Study. The placebo for BIKE contains canola oil, an inert, non-ketogenic fat,
88 commonly found in the food supply. BIKE is designed as an example of a proof-of-concept
89 geroscience clinical trial (2): specifically assessing an intervention for tolerability and safety
90 in a broad population of older adults, targeting specific aging-related molecular mechanisms,
91 and linking those mechanisms to a clinically important outcome that is broadly representative
92 of aging. We will collect exploratory data on clinical outcomes related to frailty and biological
93 aging mechanisms, which will facilitate future planned work on clinical outcomes of KE
94 consumption in a pre-frail or frail population.

95 **Methods**

96 ***Study Design Overview***

97 The Buck Institute Ketone Ester (BIKE) Study is a randomized, double-blind, placebo-
98 controlled, parallel group, pilot study designed to assess the feasibility, safety, and tolerability
99 of up to 25 g/day of KE ingestion for 12 weeks compared to a placebo in older adults (≥ 65
100 years of age), and to generate exploratory data on endpoints related to aging and frailty
101 (**Figure 1 and 2**). Following *Consent and Screening* (Visit 1), *Acute Ketone Kinetics* are
102 measured during Visit 2, *Baseline* measures are collected at Visit 3 (week 0), daily KE or
103 placebo consumption begins (day 1), an *Interim Safety* assesment is performed at Visit 4
104 (week 4), and *Final* post-intervention measures are collected at Visit 5 (week 12). Tolerance is
105 assesed during phone calls every 2 weeks. The study protocol described here has been
106 approved by Advarra Institutional Review Board (current version 1.2 approved on 17th
107 January 2023), any further ammendments will be reported to the sponsor and approved by the
108 IRB. The study is registered with clinicaltrials.gov (NCT05585762), all items from the WHO
109 Trial Registration Dataset are included in Supplementary Table 1. Recruitment for the study
110 began on November 28th 2023. Here we present details of the study protocol according to
111 SPIRIT 2013 guidelines (36) (SPIRIT checklist provided in Supplemental File)

112 ***[FIGURE 1 HERE]***

113 ***Figure : Schedule of BIKE Study screening, interventions and assessments- SPIRIT Figure***

114 ***[FIGURE 2 HERE]***

115 ***Figure 2: BIKE Study design schematic.***

116 ***Study Setting***

117 The BIKE Study is conducted by investigators and clinical research staff at The Buck Institute
118 for Research on Aging, an academic institutions based in Northern California, USA. Study

119 procedures are conducted in the Clinical Research Unit at The Buck Institute. The majority of
120 subjects are expected to be residents of Northern California.

121 ***Study Population***

122 Subjects (n = 30) in the BIKE Study are community dwelling older adults (≥ 65 years) in
123 stable health, with roughly equal distribution of male and female subjects. Equal enrollment of
124 males and females is important, as frailty is more common in women yet mortality is higher in
125 men, and detailed pathophysiology may differ between sexes (37).

126 Inclusion criteria are broad, and exclusion criteria relatively limited, in order to enroll a
127 generalizable sample of older adults. Many subjects will have common chronic diseases and
128 be taking multiple medications. Stable chronic disease and medications are not an exclusion,
129 except for specific items that may interact poorly with anticipated KE side effects such as
130 gastrointestinal upset. Inclusion and exclusion criteria are found in Table 1:

131 ***Table 1: Inclusion/Exclusion Criteria***

<i>Inclusion Criteria</i>
<ul style="list-style-type: none">• Men and women age ≥ 65 years• BMI 18.5-34.9 kg/m² (inclusive at Screening/Consent Visit)• No health conditions that would prevent them from fulfilling the study requirements as judged by the Clinical Investigator based on medical history and routine laboratory test results
<i>Exclusion Criteria</i>
<ul style="list-style-type: none">• Non ambulatory• Canadian Study of Health and Aging (CSHA) clinical frailty score > 5• Required assistance with any activity of daily living except continence• Living in an institutional setting

- Hospitalization within 30 days of the Screening/Consent Visit
- Abnormal laboratory test result(s) of clinical importance, indicating unstable chronic disease of major organ dysfunction (at the Screening/Consent Visit), at the discretion of the Clinical Investigator
- History or presence of uncontrolled and/or clinically active pulmonary, cardiac (e.g., \geq New York Heart Association class III), hepatic, renal, endocrine (including type 1 diabetes), hematologic, immunologic, neurologic (e.g., Alzheimer's or Parkinson's diseases), psychiatric (including unstable depression and/or anxiety disorders) or biliary disorders. Stable chronic disease is not an exclusion criterion unless specified
- History or presence of a clinically important gastrointestinal condition that could potentially interfere with the evaluation of the study beverage, at the discretion of the Clinical Investigator, including inflammatory bowel disease, irritable bowel syndrome, chronic constipation, severe constipation, frequent diarrhea, surgery for weight loss, gastroparesis, systemic disease that might affect gut motility, reflux requiring daily medication, gastrointestinal ulcers or bleeding and clinically important lactose intolerance
- Uncontrolled hypertension (systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg) as measured at the Screening/Consent Visit. One re-test will be allowed on a separate day prior to Visit 2
- Use of medications (over-the-counter or prescription) known to influence gastrointestinal function including, but not limited to, opioids, anti-diarrheal, and anti-spasmodic) within 30 days of the Screening/Consent, Acute Ketone Kinetics, or Baseline Visits
- Unstable use of thyroid, antihypertensive, antidepressant, or statin medications

within 6 months of the Screening/Consent, Acute Ketone Kinetics, or Baseline Visits

- Undergoing treatment or active surveillance for cancer, or has been diagnosed with cancer in the prior two years (except for non-melanoma skin cancer)
- Recently used antibiotics within 30 days of the Screening/Consent, Acute Ketone Kinetics, or Baseline Visits
- Presence of a condition that would interfere with their ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results, or put the subject at undue risk, at the discretion of the Clinical Investigator
- History of alcohol or substance abuse
- Consistent use of prescriptive or over-the-counter medications where alcohol is a contraindication, at the discretion of the Clinical Investigator
- Known allergy, intolerance, or sensitivity to any of the ingredients in the study beverages, including soy and milk protein
- Extreme dietary habits (e.g., intermittent fasting or time restricted eating, Atkins diet, vegan, very high protein/low carbohydrate) within 30 days of the Screening/Consent, Acute Ketone Kinetics, or Baseline Visits
- Use of weight-loss medications (including over-the-counter medications and/or supplements) or programs within 30 days of the Screening/Enrollment, Acute Ketone Kinetics, or Baseline Visits
- Use of ketone supplements (ketone salts or esters, and medium chain triglyceride oils) within 30 days of the Screening/Consent, Acute Ketone Kinetics, or Baseline Visits
- Working at night or shifts that will impede maintaining a consistent meal schedule

during the study

- Inability to confirm COVID-19 vaccination status
- (For female subjects) not have passed menopause, is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period

132 ***Study Intervention and Placebo***

133 The BIKE Study KE beverage is a tropical-flavored beverage containing the KE bis-octanoyl
134 (R)-1,3-butanediol (BO-BD) (BHB Therapeutics Ltd, Dublin, IRE). Each bottle is 75 mL and
135 contains 25 g of KE. This KE was developed to resolve palatability issues with the first KE
136 beverage launched by BHB Therapeutics (bis-hexanoyl (R)-1,3-butanediol, BH-BD). Both
137 BO-BD and BH-BD are expected to be metabolized similarly, and deliver a rapid increase in
138 circulating ketone concentrations (15, 16, 38, 39). Subjects will consume the study beverage
139 daily for 12 weeks at home within 5 minutes of breakfast. Half of a bottle (12.5 g KE) is
140 consumed daily during week 1, and a full bottle daily (25 g KE) for the remainder of the
141 study; this acclimation period is designed to reduce gastrointestinal issues and we have used it
142 successfully in our studies of younger adults (40). No modifications to this schedule are
143 permitted, participants may discontinue at their request or at the discretion of the study
144 medical officer. The placebo used in the study was custom manufactured by BHB
145 Therapeutics. It is matched for volume, appearance, flavor, and calories; the KE is replaced by
146 non-ketogenic canola oil. Subjects will be contacted by the study team every 2 weeks to
147 review their study product use, which is expected to improve adherence and retention.
148 Compliance will be assessed by daily completion of a paper Study Beverage Log reported by
149 study subjects. The log will be compared to the number of unopened bottles returned at week

150 4 and week 12 visits. Subjects who consume between 80 – 120% of their allocated study
151 product will be considered ‘per protocol.’

152 *Study Outcomes*

153 **Primary outcome:** The primary outcome of the BIKE Study is tolerability of the KE
154 intervention, assessed using a beverage tolerability questionnaire (BTQ) (41, 42). The BTQ
155 includes ten symptoms: gas/flatulence, nausea, vomiting, abdominal cramping, stomach
156 rumbling, burping, reflux (heartburn), diarrhea, headache, and dizziness. Subjects are either
157 asked if the issue occurred since they took the study beverage (paper questionnaire completed
158 daily 3-6 h after KE consumption during 2-week acclimation period) or during the last week
159 (completed verbally during bi-weekly telephone call), and asked to rank the intensity as none,
160 mild, moderate or severe. These correspond to scores of 0-3 respectively for each issue, giving
161 a maximal composite score of 30. After acclimation, subjects are asked to report the number
162 of days that each symptom occurred.

163 The key tolerability outcome is the proportion of subjects reporting the same moderate to
164 severe symptom (among dizziness, headache, or nausea) occurring on more than one day
165 within any given two week recall period (after week 0–2 acclimation period).

166 Headache, nausea, and dizziness were selected as they occurred significantly more often at
167 mild severity in our previous 28-day study of a KE in healthy adults (40). The ‘moderate to
168 severe’ intensity was selected as ‘mild’ symptoms are common in this population (43), and
169 may be acceptable if they are outweighed by benefits of the intervention. Moderate to severe
170 symptoms are less common (44) and more likely to be detrimental to quality of life or
171 function. The frequency of ‘more than one day per period’ is used to reduce the impact of
172 idiosyncratic symptoms on the analysis given the common occurrence of such symptoms in the
173 target population.

174 **Secondary outcomes:** Safety is a secondary outcome of the BIKE Study; assessed through
175 changes over time in clinical and laboratory measures throughout the study within each group.
176 Laboratory tests run at screening and blood samples at *Baseline, Interim Safety* and *Final*
177 *Visits* (weeks 0, 4, and 12) include hematology, chemistries, liver function tests, and thyroid
178 function tests. Based on previous data on KE effects, we are particularly focused on potassium
179 (45, 46) and bicarbonate (46, 47) along with liver function tests as KEs exploit natural hepatic
180 metabolism in generating ketone bodies. Changes in body weight, heart rate, systolic and
181 diastolic blood pressure, and orthostatic changes in blood pressure will be followed at the last
182 three study visits. KEs may increase resting heart rate (45, 48) and increase blood flow to the
183 brain and heart via vasodilation (45, 48, 49) which, while potentially therapeutic, require
184 monitoring. KEs are not associated with weight loss (40, 50, 51), but body weight is followed
185 to ensure that gastrointestinal side effects or taste do not cause clinically meaningful weight
186 loss. The key safety outcome is the longitudinal within-group change in safety blood
187 parameters. Our previous 28-day study of healthy adults did not find any clinically meaningful
188 changes in labs (40), nor were any present in other studies of KEs (50, 51). However, our
189 target population will likely include a greater proportion of potentially interacting
190 comorbidities and medications compared to these prior studies.

191 A further secondary outcome is monitoring the acute changes in blood ketone and glucose
192 concentrations for 4 h post-consumption of a serving of KE, which has not be studied in an
193 exclusively older adult cohort. At the *Acute Ketone Kinetics* Visit (Visit 2), subjects will be
194 randomly allocated to consume either 12.5g or 25 g of KE after a standard breakfast. Prior to
195 KE ingestion, and at regular intervals for 4 h following, capillary blood samples will be
196 obtained from a finger and analysed instantly for BHB and glucose concentrations using a
197 handheld device (Keto Mojo, CA, USA). We will compare the changes over the Acute Ketone
198 Kinetics study day both from $t = 0$ and between the serving size groups. A subset of subjects

199 will wear a continuous ketone monitor (Abbott, IL, USA) for the first two weeks of the study,
200 to provide data confirming the repeatability of BHB kinetics at home.

201 **Exploratory outcomes:** Exploratory outcomes include longitudinal changes in physical and
202 cognitive function, quality of life (QoL), and geroscience biomarkers in the KE and placebo
203 groups. These are assessed at *Baseline* (Visit 3, week 0) and *Final*, post-intervention (Visit 5,
204 week 12) timepoints unless otherwise stated; notably no study beverage is consumed on the
205 morning of any study visits .

206 Exploratory physical function measures will be collected at week 0 and 12 as follows: 1
207 repetition maximum (1-RM) leg press strength, 70% 1-RM leg press fatigability, 4 m gait
208 speed, Short Physical Performance Battery (SPPB), 4 m gait speed is a component of SPPB
209 but analyzed independently as well) (52), 6-minute walk test (53), grip strength via
210 dynamometer, and actigraphy via FitBit. A recent consensus statement from the International
211 Conference on Frailty and Sarcopenia Research Task Force on designing drug trials in frailty
212 recommends these measures (54). Similar outcomes were used in the CRATUS trial of
213 mesenchymal stem cells (55), ENRGISE trial of losartan and fish oil (56), LIFE physical
214 activity trial (57), and a senolytic clinical trial (58), and are proposed for TAME (59). The
215 selected measures have strong predictive value for disability (8, 60, 61). Physical performance
216 is also likely to be more dynamic in a 12-week study than longer-term clinical measures such
217 as chronic diseases or disability.

218 The exploratory cognitive measures assessed at week 0 and 12 include a standard cognitive
219 screen (Montreal Cognitive Assessment or MoCA) (62), as well as quantitative measures of
220 processing speed which are more likely to improve with the intervention within 12 weeks.
221 (Trails A, Trails B (63), and the Digit-Symbol Substitution Test or DSST (64)). MoCA and
222 Trails A/B are components of the National Alzheimer's Coordinating Center Uniform Data
223 Set Version 3 (65).

224 Other exploratory geriatric outcome measured at week 0 and 12 include Activities of Daily
225 Living (ADLs), Instrumental Activities of Daily Living (IADLs), Fried Frailty Index, and
226 CSHA Clinical Frailty Score, which are crucial assessments of overall health although
227 unlikely to change in 12 weeks (66). Quality of life measures were chosen based on relevance
228 to frailty and factors that have been anecdotally reported to change with KE use. QoL will be
229 assessed using: SF-36 (67), Profile of Mood States – Short Form (68), Sexual QoL
230 Questionnaire (Male or Female version), Pittsburgh Sleep Quality Index (69), Pittsburgh
231 Fatiguability Scale (70), and Geriatric Depression Scale (71).

232 Biomarkers in geroscience interventional clinical trials may include those related to the
233 pharmacokinetics or downstream mechanisms of the intervention, and biomarkers (2) to help
234 test if the intervention broadly impacts aging as per the Geroscience Hypothesis (72). We will
235 test exploratory biomarkers at week 0 and week 12 including: 1) blood tests identified by the
236 TAME Biomarkers Workgroup as potentially useful in an interventional trial (72), 2)
237 composite biomarkers using routine laboratory tests, 3) comprehensive 69-mer cytokine panel
238 (via the TGN Facility for Geroscience Analysis), 4) DNA methylation for use in aging clock
239 models and 5) alterations in gut microbiome using stool sample analysis at intervals through
240 the study.

241 The TAME Biomarkers Workgroup formulated criteria for biomarkers in geroscience clinical
242 trials that include feasibility and reliability, biological plausibility, robust association with
243 risk, and responsiveness to interventions (72). This resulted in a list of 9 biomarkers: IL-6,
244 CRP, sTNFR1, Cystatin C, IGF-1, NT-proBNP, insulin, GDF15, and IGFBPs. IL-6, CRP,
245 and sTNFR1 are implicated in frailty (73-75), and along with insulin, IGF-1, and IGFBPs,
246 may be directly or indirectly regulated by ketone bodies. The comprehensive 69-mer cytokine
247 panel is optimized for immunosenescence and SASP and includes TNF α , IFN γ , IL-6, IL-8,
248 IL-10, IL-17, IL1 β , sTNFR1/2, and more. We will apply three composite aging biomarkers

249 derived from routine laboratory tests: Belsky, FI-LAB and DNA methylation. Belsky et al.
250 developed two biomarkers based on the Klemra-Doubal Method and a homeostatic
251 dysregulation model and showed that the dietary restriction intervention in CALERIE slowed
252 both measures (76). FI-LAB is a clinical frailty index derived from 21 common laboratory
253 tests plus blood pressure that predicts mortality among older adults (77, 78). We will isolate
254 peripheral blood mononuclear cells for DNA methylation analysis which will allow
255 application of aging ‘clocks.’

256 The effect of KE on the human microbiome is not yet known. Ketogenic diet rapidly alters the
257 microbiome in both humans and mice, and in mice both KD and KE can reduce systemic pro-
258 inflammatory Th17 cells and alter the gut microbiota (22). To address this we will collect five
259 stool specimens from each subject (before Visit 2, before Visit 3, one week post-Visit 3,
260 immediately post- week 4, at week 12) to identify acute and chronic (across the 20 weeks)
261 changes in the microbiome.

262 *Subject Timeline*

263 For all in-person visits, subjects must meet the following pre-test criteria: fasting ≥ 10 h, no
264 alcohol ≥ 10 h, no exercise ≥ 10 h, no psychoactive cannabis products ≥ 10 h. They will be
265 queried on arrival to confirm compliance. At every visit, subjects will be queried on their use
266 of any new medications and supplement, or any changes to their health. Subjects will also be
267 queried to ensure compliance with study protocol, and will be reminded of study instructions.
268 A summary of procedures is shown in **Figure 1**.

269 **Telephone screening:** Subjects will complete a telephone screening to assess initial eligibility
270 by confirming their age, that they are independent on elements of activities of daily living
271 (ADL), any allergies, and the absence of recent hospitalizations.

272 **Screening Visit (Visit 1):** Subjects will provide written informed consent after discussing the
273 study procedures with a registered nurse and prior to collection of blood and urine samples,

274 demographic information, medical history, ADL, IADL and CSHA frailty scoring, and
275 measurement of vital signs by a registered nurse. These data will be reviewed by an
276 independent study medical officer who will make final decisions on eligibility and enrollment
277 into the study. Subjects will be asked to taste the study beverage and confirm that they are
278 willing to consume it daily for 12-weeks. Subjects will receive a stool sample kit for at-home
279 collection prior to Visit 2.

280 **Acute Ketone Kinetics Visit (Visit 2):** Subjects will be randomly allocated to either 12.5g or
281 25 g of KE following a standard breakfast (oatmeal with protein powder). Before and 4 h after
282 study beverage consumption, subjects will verbally complete the BTQ described above, to
283 determine the incidence of any side-effects during the visit. Capillary blood samples will be
284 obtained by a research associate from a finger using a lancing device, and analyzed instantly
285 for BHB and glucose concentrations using a handheld device (KetoMojo, CA, USA).
286 Collection time points are: pre-consumption, 30-, 60-, 90-, 120-, 180- and 240-minutes post-
287 consumption. Study staff are not blinded to serving size for this visit. Subjects will be
288 familiarized with the physical function tests that will be completed at Visit 3, and receive
289 instruction on how to capture one day's food intake with an online diet log (ASA-24,
290 NCI(79)) and be given a FitBit Inspire 2 device (FitBit, CA, USA) to wear for the remainder
291 of the study in addition to a second stool sample kit for at-home collection prior to Visit 3.

292 **Baseline Visit (Visit 3, week 0):** Fasted blood and urine samples will be collected for analysis
293 as described above. Vital signs will be assessed after subjects have completed QoL
294 questionnaires. Physical and cognitive function will be tested as described above; tests will be
295 performed by a trained and certified (where appropriate) registered nurses or research
296 associates. A continuous ketone monitor will be applied to a subset of subjects. Subjects will
297 be given the Study Beverage Log that will be completed each day at home, a stool sample kit

298 for at-home collection one week after Visit 3, and a one-month supply of their study beverage,
299 plus overage (35 bottles).

300 **At-home procedures:** Subjects will consume the study beverage every day for 12-weeks
301 within 5 minutes after their breakfast. For the first week, they will consume half of a bottle
302 daily (12.5 g KE), and for the remainder of the study they will consume a full bottle daily (25
303 g KE). They will complete a Study Beverage Log to indicate time of product consumption.
304 Additionally, for the first two weeks (acclimation period), a full BTQ will be completed each
305 day. For the remainder of the study, an open-ended question will allow subjects to record any
306 side effects that they experience each day. The Study Log will be reviewed for compliance
307 and BTQ outcomes during bi-weekly phone calls (week 2, 6, 8 and 10) and at Visit 4 and Visit
308 5. Adverse events (AEs) will also be queried during each phone call. The final month's supply
309 of product will be mailed to subjects during week 7, along with a stool sample kit for at home
310 collection up to 3 days before Visit 5.

311 **Interim Safety Visit (Visit 4, week 4):** Tolerability will be assessed by verbal completion of
312 the BTQ, and AEs will be queried. Fasted blood and urine samples will be collected for safety
313 lab analysis. Adherence will be monitored by review of the Study Beverage Log and counting
314 of unused bottles of product brought in by the subject. One months' supply of product plus
315 overage (35 bottles) will be provided for subjects to take home, along with a new Study
316 Beverage Log. Subjects will be given a stool sample kit for at home collection 3 days after
317 Visit 4. The independent study medical officer will review the safety lab results to approve
318 continuation of subjects in the study.

319 **Final Visit (Visit 5, week 12):**

320 The Final Visit is identical to the Baseline Visit, except that the following will not take place:
321 application of continuous ketone monitor, provision of study beverage, and Study Beverage

322 Log distribution. The following will take place: collection of Study Beverage Log, compliance
323 monitoring, verbal BTQ administration, and AEs query.

324 ***Sample size***

325 Based on studies of symptoms in older adults (43, 44), we predict the primary outcome rate in
326 the placebo group will be approximately 10%. N = 30 (15 per arm) provides 36% power to
327 detect a 25% increase (from 10% to 35%) in the proportion of subjects meeting this primary
328 outcome in the KE condition with two-sided $\alpha=0.10$. If we assume a larger effect of the KE
329 intervention, n = 30 (15 per arm) provides approximately 75% power to detect an increase
330 (from 10% to 55%) in the proportion of subjects meeting this primary outcome in the KE
331 condition, with two-sided $\alpha=0.10$.

332 ***Recruitment***

333 Initial recruitment is via sharing of study information on the Buck Institute website, outreach
334 to a voluntary mailing list of interested individuals maintained by the Buck Institute, and via
335 response to public outreach including a local newspaper article and talks at community group
336 events. Further recruitment plans include ongoing engagement with community groups
337 serving older adults, outreach to organizations representing communities underrepresented in
338 medicine, and flyer mailings targeted to communities underrepresented in medicine.

339 ***Allocation and Blinding***

340 Study beverage sequence allocation will occur randomly, based on a block allocation sequence
341 prepared by a statistician. It will result in a 1:1:1:1 breakdown of subjects to receive either
342 12.5 or 25 g of KE at the *Acute Ketone Kinetics* Visit, and then either KE or placebo beverage
343 for the 12-week study. Stratification by sex will occur to ensure equal allocation to each
344 group. Allocation will occur at Visit 2, with the sequence assigned by the research team in the
345 order of subject enrollment.

346 Study beverage will be coded and labelled by external personnel and all study staff will
347 remain blinded to the code allocation of the beverage throughout the study, but not the group
348 allocation of the subject. Unblinding will occur after completion of all subjects and after
349 analysis of the primary data outcome by an external statistician. Written procedures govern
350 emergency unblinding of individuals or the study as a whole. Individual subjects are provided
351 with a pocket card including their allocation code and a description of anticipated possible
352 clinical effects of KE. They will have their allocation revealed to them and their health care
353 providers via the study medical officers (in consultation with the principal investigator) if it is
354 determined that unblinding is necessary for the care of an adverse event. In such an instance,
355 allocation coding will remain blinded to the principal investigator, study staff, and all other
356 subjects.

357 ***Subject Retention***

358 Retention will be facilitated by building rapport with subjects during early study visits and
359 ongoing bi-weekly contact with study subjects via telephone calls as well as email reminders
360 of upcoming visits. In addition, stipends will be paid at the end of each visit; the value of the
361 stipend increases each visit to incentivize continued participation.

362 ***Data Management and Dissemination***

363 Data will be entered into paper case report forms (CRFs) during study visits by research
364 associates or registered nurses and reviewed for completeness by an investigator before it is
365 transcribed into an electronic datasheet. Every effort will be made to maintain subject
366 confidentiality before, during, and after the study. CRFs and entries into the electronic data
367 sheet are identified by subject number, and the code-break linking the subjects' name to their
368 study number is stored separately to the CRFs. CRFs are kept in secure cabinet in a room with
369 limited access. The electronic datasheet is stored on a secure internal server at The Buck
370 Institute. Data will be spot-checked for quality during the study closure, and retained for up to

371 5 years after closure.

372 Research data will be shared according to the most recent NIH guidelines. We are committed
373 to the sharing of final research data, being mindful that the rights and privacy of people who
374 participate in research must be protected at all times and that there is the need to protect
375 patentable and other proprietary data. Any datasets will be free of any identifiers that would
376 permit linkages to individual research participants and variables that could lead to deductive
377 disclosure of individual subjects. Anonymized raw, subject-level data will be held at The Buck
378 Institute under the custody of the Principal Investigator and de-identified data will be made
379 available upon reasonable written request to the PI. The results of the study will be
380 disseminated via publication in scientific papers, abstracts, and presentations. Authorship will
381 be determined by ICMJE guidelines, manuscripts will be prepared by the study team.

382 *Statistical Analysis*

383 All analyses will be based on intention to treat and will be conducted by an external study
384 statistician who will be blinded to intervention coding. The proportion of subjects with the
385 primary outcome will be compared between groups with Fisher's exact test. The frequency of
386 each individual symptom and the frequency of mild symptoms will be explored with
387 categorical data analysis methods. The total composite scores will be evaluated with a
388 Wilcoxon rank sum test. During the 14-day acclimation period, the daily composite score will
389 be calculated as the sum of the individual items and will be analyzed with a random
390 coefficient model. The within-group change in safety labs will be compared between groups
391 with a Wilcoxon rank sum test and a false discovery rate adjustment to control for multiple
392 comparisons. Changes in continuous secondary and exploratory outcomes will be compared
393 between groups with an analysis of covariance approach or a repeated measures model. The
394 intent-to-treat (ITT) population will comprise data for all subjects who were randomized and
395 consumed one serving of the study beverage. In addition, the per protocol (PP) population

396 will be identified as a subset of the ITT population, in which subjects will be excluded for the
397 following reasons and possibly others: violations of inclusion or exclusion criteria that could
398 influence the evaluation of response, non-compliance by the subject, including, but not
399 limited to: use of prohibited drugs or any products thought to alter the primary outcome
400 variable during the study, less than 80% or more than 120% compliance with study beverage
401 consumption, or not adhering to instructions as outlined in the protocol. All decisions
402 regarding exclusion from the ITT and PP populations will be documented prior to database
403 lock. Missing data will not be imputed.

404 ***Safety Monitoring and Oversight***

405 Remote and on-site monitoring visits will be conducted periodically during the study, focusing
406 on human subject protection and data integrity risks of the trial. A clinical monitoring plan
407 will be developed which identifies specific risk-based monitoring focal points. These may
408 include: informed consent, eligibility criteria, adverse events, protocol deviations, endpoints,
409 study beverage accountability.

410 Independent study medical officers will be retained to monitor the study data, they will be
411 practicing physicians with expertise in geriatric medicine. The medical officers will make final
412 determinations on all study enrollment, continuation (*Interim Safety Visit*), and discontinuation
413 decisions, as well as review any serious adverse events and events of note, and consult with
414 the study team on any other adverse events. The Buck Institute designated an institutional
415 officer to represent the Institute and the philanthropic funders .

416 Adverse events will be queried at visits and telephone calls and recorded in the CRF. Serious
417 adverse events will be reported to the medical officers, institutional officer, and the IRB.
418 'Events of note' are a subset of adverse events that result in discontinuation from the study,
419 require treatment or require diagnostic evaluation. No interim analysis is planned, however if a
420 pre-determined threshold of excess events of note occurring in one of the study groups is

421 reached, or if a serious adverse event occurs the committee comprising of the medical officers,
422 institutional officers, and principal investigator will convene to discuss unblinding and study
423 pausing or discontinuation. No medical care will be provided during the study and no form of
424 compensation is offered for any injury.

425 *Discussion*

426 This pilot study will provide important new information on the application of ketone
427 body biology to human health and disease in aging. Firstly, KEs have not been rigorously
428 tested in older adults, therefore the data resulting from this study will support further research
429 with KEs in other age-related conditions. Secondly, the particular KE under investigation here
430 is more palatable than existing products, and as it requires endogenous production of ketone
431 bodies from the fatty acid components it more closely mimics dietary ketosis. Thirdly, this
432 will be the most direct test to date of KE effects on geroscience pathways in humans,
433 beginning to extend into humans the extensive pre-clinical literature linking ketosis to aging
434 mechanisms. Fourthly, as ketone bodies are generated endogenously during both caloric
435 restriction and exercise, KE can provide more specific mechanistic insight into the clinical
436 effects of such interventions as in the NIH-funded CALERIE and HALLO-P trials. Finally,
437 this is intended to be an example of an early proof-of-concept clinical trial testing the
438 biological effects of a geroscience-guided intervention, with many elements of its design
439 based on frameworks developed by the NIH-funded Translational Geroscience Network (2).
440 These design and conceptual elements include the goal of specifically assessing safety in an
441 older population, focusing on a broadly representative and generalizable population, the use of
442 functional outcome measures, and the combination of intervention-specific with general aging
443 biomarkers. Translational geroscience is an emerging field, and early-stage clinical trials have
444 been identified as the key bottleneck in the development of interventions, as well as being
445 critical for training the next generation of investigators (80).

446 The need to carefully balance safety in a less resilient population with the desire to
447 generate meaningful data in our exploratory outcomes led to the selection of the 12-week
448 study duration. Studies of KEs in younger adults have demonstrated safety over a 28-day
449 study period, hence 12-weeks represents a significant extension of the existing data. The

450 Interim Safety Visit (Visit 4, week 4) is designed to ensure that subjects do not continue in the
451 study if clinically meaningful negative changes to blood safety labs occur. Assuming positive
452 safety and tolerability findings in this population, the study duration could be extended in
453 future work.

454 Similarly, serving size selection for this study took into consideration multiple factors
455 including feasibility, safety, and likely efficacy. Some functional endpoints, such as cognition
456 (81) and cardiac function (45), appear to be responsive to the blood concentration of BHB ,
457 hence giving the maximal tolerable KE serving size could increase the chance of observing
458 KE efficacy. Whilst some KEs have been studied at serving sizes up to 75 g/day for 28 days,
459 the KE family used in this study has only been studied up to 25 g/day for 28 days, hence why
460 the 25 g serving size was selected for this first-in-older-adults 12-week study. Splitting the
461 daily serving into multiple smaller boluses through the day may have provided greater total
462 time in nutritional ketosis for each study day, however there is no definitive evidence to
463 support increased time in ketosis vs. a higher BHB peak. Increasing the subject burden and
464 thus increasing the chance of non-adherence or drop-outs by requiring twice daily
465 consumption was identified as a more important consideration than consistent ketosis
466 coverage, hence why 25 g/day servings in one bolus was chosen. If safety data for this KE
467 were expanded, larger serving sizes could be implemented in future work.

468 Study population selection was another area of careful consideration. Whilst the study
469 is intended to recruit healthy individuals, older adults unavoidably have a greater incidence of
470 concurrent health conditions and medication use. Requiring no medication use and no active
471 conditions would be prohibitive for recruitment in an older adult population, and would both
472 exclude the pathophysiology of interest while sharply limiting relevance and generalizability
473 to the majority of older adults. With this in mind, we set intentionally broad inclusion and
474 exclusion criteria; as subjects must be independent for all activities of daily living (excluding

475 self-managed continence issues) and we explicitly exclude a range of relevant active and
476 unstable conditions, this will exclude most actively unwell individuals. The aim is to include
477 healthy older adults, accepting that this includes individuals who are managing some health
478 conditions.

479 The field of geroscience translational clinical trials is relatively new and
480 standardization of outcome measures across studies presents both challenges and opportunities
481 (2). The outcome measures included in this study were chosen based on their hypothesized
482 sensitivity to our KE intervention and to harmonize between other innovative geroscience
483 clinical trials, the latter representing a major strength of this protocol. The ability to compare
484 between study populations will inform the clinical significance of any changes following the
485 KE intervention compared with other proposed geroscience interventions. Although some of
486 the exploratory outcome measures are unlikely to change over the study period in a healthy
487 population (i.e., ADL, IADL, SPBB, MoCA), others may be more dynamic (i.e., blood
488 biomarkers, grip strength, 1-RM). Future work in a frail or pre-frail population, with a longer
489 study period and increased KE serving size, would increase the probability of detecting
490 significant changes in these measures.

491 **Sources of Funding, Author Declarations and Conflict Management:**

492 Funding for BIKE is provided by philanthropic donations from Dr James B. Johnson and
493 from members of the Buck Institute Impact Circle. Dr Johnson assisted with
494 conceptualization of the study and reviewed this manuscript but has no further role in study
495 design, management, data collection, analysis, interpretation of data, decision to submit
496 publications, or writing of publications. The Buck Institute Impact Circle has no role in
497 conceptualization, study design, management, data collection, analysis, interpretation of data,
498 decision to submit publications, review, or writing of publications.

499 Dr Newman's participation in the study is supported by Buck Institute institutional funds. Dr
500 Brianna Stubbs' participation in the study is supported by supported by the NIH (NIA) under
501 award number K01AG078125.

502 The KE intervention is provided gratis by BHB Therapeutics Ltd (Ireland). BHB
503 Therapeutics also arranged for manufacture of the matched placebo, paid from BIKE study
504 funds. BHB Therapeutics markets formulated KE beverages to consumers. BHB
505 Therapeutics provided no funding for the study, and has no role in the design, management,
506 data collection, analysis, interpretation of data, decision to submit publications, or writing of
507 publications.

508 The principal investigator (Dr. Newman), Dr. Brianna Stubbs, and the Buck Institute hold
509 shares in BHB Therapeutics. Drs. Newman and Stubbs are inventors on patents relating to the
510 use of ketone bodies that are assigned to The Buck Institute. All other authors have no
511 conflicts to declare. Individual and institutional extensive conflict management plans were
512 developed and approved by the Buck Institute and the IRB. Actions and decisions important
513 to subject safety and study integrity are carried out by parties with no potential financial
514 conflict. Participant consent is obtained by licensed registered nurses who have no financial
515 conflict. Decisions on subject enrollment, continuation, and discontinuation are made by

516 independent medical officers unaffiliated with Buck Institute and with no financial conflict.
517 Data analysis for the primary outcome is carried out by an independent statistician with no
518 financial conflict. Study staff, including the principal investigator, will maintain blinding
519 through study completion unless unblinding is required for safety concerns.

520 **Author Contributions:** Conceptualization, J.C.N, J.B.J, B.J.S.; methodology, all; writing—
521 original draft preparation, G.A.A, B.J.S; writing—review and editing all; visualization, B.J.S,
522 J.C.N; project administration, B.J.S, J.C.N, T.G; supervision: B.J.B, T.G, J.C.N; funding
523 acquisition, B.J.S, J.C.N; All authors have read and agreed to the published version of the
524 manuscript.

525 **Institutional Review Board Statement:** This study will be conducted according to the
526 guidelines of the Declaration of Helsinki (2004), and the first version of the study documents
527 were approved by Advava IRB on September 28, 2022 (current version was approved 17th
528 January 2023).

Reference List

529

530

531 1. Newman JC, Milman S, Hashmi SK, Austad SN, Kirkland JL, Halter JB, et al.
532 Strategies and Challenges in Clinical Trials Targeting Human Aging. *J Gerontol A Biol Sci*
533 *Med Sci.* 2016;71(11):1424-34.

534 2. Justice J, Miller JD, Newman JC, Hashmi SK, Halter J, Austad SN, et al. Frameworks
535 for Proof-of-Concept Clinical Trials of Interventions That Target Fundamental Aging
536 Processes. *J Gerontol A Biol Sci Med Sci.* 2016;71(11):1415-23.

537 3. Dent E, Martin FC, Bergman H, Woo J, Romero-Ortuno R, Walston JD. Management
538 of frailty: opportunities, challenges, and future directions. *Lancet.* 2019;394(10206):1376-86.

539 4. Bandeen-Roche K, Seplaki CL, Huang J, Buta B, Kalyani RR, Varadhan R, et al.
540 Frailty in Older Adults: A Nationally Representative Profile in the United States. *J Gerontol*
541 *A Biol Sci Med Sci.* 2015;70(11):1427-34.

542 5. Zampino M, Brennan NA, Kuo PL, Spencer RG, Fishbein KW, Simonsick EM, et al.
543 Poor mitochondrial health and systemic inflammation? Test of a classic hypothesis in the
544 Baltimore Longitudinal Study of Aging. *Geroscience.* 2020;42(4):1175-82.

545 6. Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular
546 disease, and frailty. *Nature reviews Cardiology.* 2018;15(9):505-22.

547 7. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging:
548 An expanding universe. *Cell.* 2023;186(2):243-78.

549 8. Walston J, Buta B, Xue QL. Frailty Screening and Interventions: Considerations for
550 Clinical Practice. *Clin Geriatr Med.* 2018;34(1):25-38.

551 9. Green CL, Lamming DW, Fontana L. Molecular mechanisms of dietary restriction
552 promoting health and longevity. *Nat Rev Mol Cell Biol.* 2022;23(1):56-73.

553 10. Rickman AD, Williamson DA, Martin CK, Gilhooly CH, Stein RI, Bales CW, et al.
554 The CALERIE Study: design and methods of an innovative 25% caloric restriction
555 intervention. *Contemp Clin Trials.* 2011;32(6):874-81.

556 11. Cahill GF, Jr. Fuel metabolism in starvation. *Annual Review of Nutrition.* 2006;26:1-
557 22.

558 12. Newman JC, Verdin E. beta-Hydroxybutyrate: A Signaling Metabolite. *Annual*
559 *review of nutrition.* 2017;37:51-76.

560 13. Roberts MN, Wallace MA, Tomilov AA, Zhou Z, Marcotte GR, Tran D, et al. A
561 Ketogenic Diet Extends Longevity and Healthspan in Adult Mice. *Cell Metabolism.*
562 2017;26(3):539-46.e5.

- 563 14. Newman JC, Covarrubias AJ, Zhao M, Yu X, Gut P, Ng C-P, et al. Ketogenic Diet
564 Reduces Midlife Mortality and Improves Memory in Aging Mice. *Cell metabolism*.
565 2017;26(3):547-57.e8.
- 566 15. Crabtree CD, Blade T, Hyde PN, Buga A, Kackley ML, Sapper TN, et al. Bis
567 Hexanoyl (R)-1,3-Butanediol, a Novel Ketogenic Ester, Acutely Increases Circulating r- and
568 s-ss-Hydroxybutyrate Concentrations in Healthy Adults. *J Am Nutr Assoc*. 2022:1-9.
- 569 16. Stubbs BJ, Cook C, Blonquist TM, Taggart K, Beckman D, Kruger C, et al. A
570 randomized, open-label, cross-over pilot study investigating metabolic product kinetics of the
571 palatable novel ketone ester, bis-octanoyl (R)-1,3-butanediol, and bis-hexanoyl (R)-1,3-
572 butanediol ingestion in healthy adults. *Toxicology Research*. 2023 (submitted).
- 573 17. Stubbs BJ, Blade T, Mills S, Thomas J, Yufei X, Nelson FR, et al. In vitro stability
574 and in vivo pharmacokinetics of the novel ketogenic ester, bis hexanoyl (R)-1,3-butanediol.
575 *Food Chem Toxicol*. 2021;147:111859.
- 576 18. Koutnik AP, Poff AM, Ward NP, DeBlasi JM, Soliven MA, Romero MA, et al.
577 Ketone Bodies Attenuate Wasting in Models of Atrophy. *J Cachexia Sarcopenia Muscle*.
578 2020.
- 579 19. Koutnik AP, D'Agostino DP, Egan B. Anticatabolic Effects of Ketone Bodies in
580 Skeletal Muscle. *Trends Endocrinol Metab*. 2019;30(4):227-9.
- 581 20. Yurista SR, Matsuura TR, Sillje HHW, Nijholt KT, McDaid KS, Shewale SV, et al.
582 Ketone Ester Treatment Improves Cardiac Function and Reduces Pathologic Remodeling in
583 Preclinical Models of Heart Failure. *Circ Heart Fail*. 2021;14(1):e007684.
- 584 21. Horton JL, Davidson MT, Kurishima C, Vega RB, Powers JC, Matsuura TR, et al.
585 The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense. *JCI Insight*.
586 2019;4(4).
- 587 22. Ang QY, Alexander M, Newman JC, Tian Y, Cai J, Upadhyay V, et al. Ketogenic
588 Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells. *Cell*.
589 2020;181(6):1263-75.e16.
- 590 23. Goldberg EL, Molony RD, Kudo E, Sidorov S, Kong Y, Dixit VD, et al. Ketogenic
591 diet activates protective $\gamma\delta$ T cell responses against influenza virus infection. *Sci Immunol*.
592 2019;4(41).
- 593 24. Falkenhain K, Daraei A, Forbes SC, Little JP. Effects of Exogenous Ketone
594 Supplementation on Blood Glucose: A Systematic Review and Meta-Analysis. *Adv Nutr*.
595 2022.
- 596 25. Greaves G, Xiang R, Rafiei H, Malas A, Little JP. Prior ingestion of a ketone
597 monoester supplement reduces postprandial glycemic responses in young healthy-weight
598 individuals. *Appl Physiol Nutr Metab*. 2021;46(4):309-17.

- 599 26. Myette-Côté É, Caldwell HG, Ainslie PN, Clarke K, Little JP. A ketone monoester
600 drink reduces the glycemic response to an oral glucose challenge in individuals with obesity:
601 a randomized trial. *The American Journal of Clinical Nutrition*. 2019;110(6):1491-501.
- 602 27. Myette-Cote E, Neudorf H, Rafiei H, Clarke K, Little JP. Prior ingestion of
603 exogenous ketone monoester attenuates the glycaemic response to an oral glucose tolerance
604 test in healthy young individuals. *J Physiol*. 2018;596(8):1385-95.
- 605 28. Cox PJ, Kirk T, Ashmore T, Willerton K, Evans R, Smith A, et al. Nutritional Ketosis
606 Alters Fuel Preference and Thereby Endurance Performance in Athletes. *Cell Metabolism*.
607 2016;24:1-13.
- 608 29. Poffe C, Ramaekers M, Bogaerts S, Hespel P. Bicarbonate Unlocks the Ergogenic
609 Action of Ketone Monoester Intake in Endurance Exercise. *Med Sci Sports Exerc*.
610 2021;53(2):431-41.
- 611 30. Poffe C, Ramaekers M, Van Thienen R, Hespel P. Ketone ester supplementation
612 blunts overreaching symptoms during endurance training overload. *J Physiol*.
613 2019;597(12):3009-27.
- 614 31. Coleman K, Phillips J, Sciarini M, Stubbs B, Jackson O, Kernagis D. A Metabolic
615 Intervention for Improving Human Cognitive Performance During Hypoxia. *Aerospace
616 medicine and human performance*. 2021;92(7):556-62.
- 617 32. Evans M, Egan B. Intermittent Running and Cognitive Performance after Ketone
618 Ester Ingestion. *Med Sci Sports Exerc*. 2018;50(11):2330-8.
- 619 33. Walsh JJ, Caldwell HG, Neudorf H, Ainslie PN, Little JP. Short-term ketone
620 monoester supplementation improves cerebral blood flow and cognition in obesity: A
621 randomized cross-over trial. *J Physiol*. 2021;599(21):4763-78.
- 622 34. Neudorf H, Myette-Côté É, P. Little J. The Impact of Acute Ingestion of a Ketone
623 Monoester Drink on LPS-Stimulated NLRP3 Activation in Humans with Obesity. *Nutrients*.
624 2020;12(3).
- 625 35. Selvaraj S, Hu R, Vidula MK, Dugyala S, Tierney A, Ky B, et al. Acute
626 Echocardiographic Effects of Exogenous Ketone Administration in Healthy Participants. *J
627 Am Soc Echocardiogr*. 2022;35(3):305-11.
- 628 36. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al.
629 SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Ann Intern Med*.
630 2013;158(3):200-7.
- 631 37. Gordon EH, Peel NM, Samanta M, Theou O, Howlett SE, Hubbard RE. Sex
632 differences in frailty: A systematic review and meta-analysis. *Exp Gerontol*. 2017;89:30-40.

- 633 38. Mah E, Blonquist TM, Kaden VN, Beckman D, Boileau AC, Anthony JC, et al. A
634 randomized, open-label, parallel pilot study investigating metabolic product kinetics of the
635 novel ketone ester, bis-hexanoyl (R)-1,3-butanediol, over one week of ingestion in healthy
636 adults. *Front Physiol.* 2023;14.
- 637 39. Nieman KM, Anthony JC, Stubbs BJ. A Novel Powder Formulation of the Ketone
638 Ester, Bis Hexanoyl (R)-1,3-Butanediol, Rapidly Increases Circulating ss-Hydroxybutyrate
639 Concentrations in Healthy Adults. *J Am Nutr Assoc.* 2022:1-8.
- 640 40. Chen O, Blonquist TM, Mah E, Sanoshy K, Beckman D, Nieman KM, et al.
641 Tolerability and Safety of a Novel Ketogenic Ester, Bis-Hexanoyl (R)-1,3-Butanediol: A
642 Randomized Controlled Trial in Healthy Adults. *Nutrients.* 2021;13(6).
- 643 41. Boler BM, Serao MC, Bauer LL, Staeger MA, Boileau TW, Swanson KS, et al.
644 Digestive physiological outcomes related to polydextrose and soluble maize fibre
645 consumption by healthy adult men. *Br J Nutr.* 2011;106(12):1864-71.
- 646 42. Maki KC, Rains TM, Kelley KM, Cook CM, Schild AL, Gietl E. Fibermalt is well
647 tolerated in healthy men and women at intakes up to 60 g/d: a randomized, double-blind,
648 crossover trial. *Int J Food Sci Nutr.* 2013;64(3):274-81.
- 649 43. Han MA, Tinetti ME, Agostini JV, Han L, Lee H, Walke LM. The impact of
650 medication use on symptom burden in older patients with multiple medical morbidities.
651 *Journal of Clinical Gerontology and Geriatrics.* 2013;4(3):84-8.
- 652 44. Chaudhry SI, Murphy TE, Gahbauer E, Sussman LS, Allore HG, Gill TM. Restricting
653 symptoms in the last year of life: a prospective cohort study. *JAMA Intern Med.*
654 2013;173(16):1534-40.
- 655 45. Nielsen R, Moller N, Gormsen LC, Tolbod LP, Hansson NH, Sorensen J, et al.
656 Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic
657 Heart Failure Patients. *Circulation.* 2019;139(18):2129-41.
- 658 46. Stubbs BJ, Cox PJ, Evans RD, Santer P, Miller JJ, Faull OK, et al. On the Metabolism
659 of Exogenous Ketones in Humans. *Front Physiol.* 2017;8:848.
- 660 47. Dearlove DJ, Faull OK, Rolls E, Clarke K, Cox PJ. Nutritional Ketoacidosis During
661 Incremental Exercise in Healthy Athletes. *Front Physiol.* 2019;10:290.
- 662 48. Gormsen LC, Svart M, Thomsen HH, Sondergaard E, Vendelbo MH, Christensen N,
663 et al. Ketone Body Infusion With 3-Hydroxybutyrate Reduces Myocardial Glucose Uptake
664 and Increases Blood Flow in Humans: A Positron Emission Tomography Study. *J Am Heart
665 Assoc.* 2017;6(3):e005066.
- 666 49. Svart M, Gormsen LC, Hansen J, Zeidler D, Gejl M, Vang K, et al. Regional cerebral
667 effects of ketone body infusion with 3-hydroxybutyrate in humans: Reduced glucose uptake,

- 668 unchanged oxygen consumption and increased blood flow by positron emission tomography.
669 A randomized, controlled trial. *PLoS One*. 2018;13(2):e0190556.
- 670 50. Soto-Mota A, Vansant H, Evans RD, Clarke K. Safety and tolerability of sustained
671 exogenous ketosis using ketone monoester drinks for 28 days in healthy adults. *Regul*
672 *Toxicol Pharmacol*. 2019;109:104506.
- 673 51. Soto-Mota A, Norwitz NG, Evans R, Clarke K, Barber TM. Exogenous ketosis in
674 patients with type 2 diabetes: Safety, tolerability and effect on glycaemic control.
675 *Endocrinology, Diabetes & Metabolism*. 2021.
- 676 52. McElhaney JE, Effros RB. Immunosenescence: what does it mean to health outcomes
677 in older adults? *Curr Opin Immunol*. 2009;21(4):418-24.
- 678 53. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med*.
679 2002;166(1):111-7.
- 680 54. Pahor M, Kritchevsky SB, Waters DL, Villareal DT, Morley J, Hare JM, et al.
681 Designing Drug Trials for Frailty: ICFSR Task Force 2018. *J Frailty Aging*. 2018;7(3):150-4.
- 682 55. Tompkins BA, DiFede DL, Khan A, Landin AM, Schulman IH, Pujol MV, et al.
683 Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized,
684 Double-Blind, Placebo-Controlled Clinical Trial. *J Gerontol A Biol Sci Med Sci*.
685 2017;72(11):1513-22.
- 686 56. Manini TM, Anton SD, Beavers DP, Cauley JA, Espeland MA, Fielding RA, et al.
687 ENabling Reduction of Low-grade Inflammation in SENiors Pilot Study: Concept, Rationale,
688 and Design. *Journal of the American Geriatrics Society*. 2017;65(9):1961-8.
- 689 57. Pahor M, Guralnik JM, Ambrosius WT, Blair S, Bonds DE, Church TS, et al. Effect
690 of structured physical activity on prevention of major mobility disability in older adults: the
691 LIFE study randomized clinical trial. *Jama*. 2014;311(23):2387-96.
- 692 58. Justice JN, Nambiar AM, Tchkonja T, LeBrasseur NK, Pascual R, Hashmi SK, et al.
693 Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot
694 study. *EBioMedicine*. 2019;40:554-63.
- 695 59. Justice JN, Niedernhofer L, Robbins PD, Aroda VR, Espeland MA, Kritchevsky SB,
696 et al. Development of Clinical Trials to Extend Healthy Lifespan. *Cardiovasc Endocrinol*
697 *Metab*. 2018;7(4):80-3.
- 698 60. Perera S, Patel KV, Rosano C, Rubin SM, Satterfield S, Harris T, et al. Gait Speed
699 Predicts Incident Disability: A Pooled Analysis. *The Journals of Gerontology: Series A*.
700 2016;71(1):63-71.

- 701 61. Enright PL, McBurnie MA, Bittner V, Tracy RP, McNamara R, Arnold A, et al. The
702 6-min walk test: a quick measure of functional status in elderly adults. *Chest*.
703 2003;123(2):387-98.
- 704 62. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et
705 al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive
706 impairment. *J Am Geriatr Soc*. 2005;53(4):695-9.
- 707 63. Reitan RM. Validity of the Trail Making Test as an Indicator of Organic Brain
708 Damage. *Perceptual and Motor Skills*. 1958;8(3):271-6.
- 709 64. Swindell WR, Cummings SR, Sanders JL, Caserotti P, Rosano C, Satterfield S, et al.
710 Data mining identifies Digit Symbol Substitution Test score and serum cystatin C as
711 dominant predictors of mortality in older men and women. *Rejuvenation Res*.
712 2012;15(4):405-13.
- 713 65. Weintraub S, Besser L, Dodge HH, Teylan M, Ferris S, Goldstein FC, et al. Version 3
714 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set
715 (UDS). *Alzheimer Dis Assoc Disord*. 2018;32(1):10-7.
- 716 66. Gill TM, Gahbauer EA, Allore HG, Han L. Transitions between frailty states among
717 community-living older persons. *Arch Intern Med*. 2006;166(4):418-23.
- 718 67. Walters SJ, Brazier JE. What is the relationship between the minimally important
719 difference and health state utility values? The case of the SF-6D. *Health Qual Life Outcomes*.
720 2003;1:4.
- 721 68. Curran S, Andrykowski M, Studts J. Short Form of the Profile of Mood States
722 (POMS-SF): Psychometric information.. . *Psychol Assess*. 1995;7:80-3.
- 723 69. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep
724 quality index: A new instrument for psychiatric practice and research. *Psychiatry Res*.
725 1989;28(2):193-213.
- 726 70. Glynn NW, Santanasto AJ, Simonsick EM, Boudreau RM, Beach SR, Schulz R, et al.
727 The Pittsburgh Fatigability scale for older adults: development and validation. *J Am Geriatr
728 Soc*. 2015;63(1):130-5.
- 729 71. Yesavage JA, Sheikh JI. Geriatric Depression Scale (GDS). *Clin Gerontol*. 2008;5(1-
730 2):165-73.
- 731 72. Justice JN, Ferrucci L, Newman AB, Aroda VR, Bahnson JL, Divers J, et al. A
732 framework for selection of blood-based biomarkers for geroscience-guided clinical trials:
733 report from the TAME Biomarkers Workgroup. *Geroscience*. 2018;40(5-6):419-36.

- 734 73. Marcos-Pérez D, Sánchez-Flores M, Proietti S, Bonassi S, Costa S, Teixeira JP, et al.
735 Association of inflammatory mediators with frailty status in older adults: results from a
736 systematic review and meta-analysis. *Geroscience*. 2020;42(6):1451-73.
- 737 74. Kane AE, Sinclair DA. Frailty biomarkers in humans and rodents: Current approaches
738 and future advances. *Mech Ageing Dev*. 2019;180:117-28.
- 739 75. Chen X, Mao G, Leng SX. Frailty syndrome: an overview. *Clin Interv Aging*.
740 2014;9:433-41.
- 741 76. Belsky DW, Huffman KM, Pieper CF, Shalev I, Kraus WE. Change in the Rate of
742 Biological Aging in Response to Caloric Restriction: CALERIE Biobank Analysis. *J*
743 *Gerontol A Biol Sci Med Sci*. 2017;73(1):4-10.
- 744 77. Howlett SE, Rockwood MR, Mitnitski A, Rockwood K. Standard laboratory tests to
745 identify older adults at increased risk of death. *BMC Med*. 2014;12:171.
- 746 78. Rockwood K, McMillan M, Mitnitski A, Howlett SE. A Frailty Index Based on
747 Common Laboratory Tests in Comparison With a Clinical Frailty Index for Older Adults in
748 Long-Term Care Facilities. *J Am Med Dir Assoc*. 2015;16(10):842-7.
- 749 79. NCI. Automated Self-Administered 24-Hour (ASA24®) Dietary Assessment Tool
750 [Available from: <https://epi.grants.cancer.gov/asa24/>].
- 751 80. Newman JC, Sokoloski JL, Robbins PD, Niedernhofer LJ, Reed MJ, Wei J, et al.
752 Creating the Next Generation of Translational Geroscientists. *J Am Geriatr Soc*.
753 2019;67(9):1934-9.
- 754 81. Fortier M, Castellano CA, St-Pierre V, Myette-Cote E, Langlois F, Roy M, et al. A
755 ketogenic drink improves cognition in mild cognitive impairment: Results of a 6-month RCT.
756 *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2021;17(3):543-52.
757

Visit Name	Phone Screen	Screening/ Consent Visit (1)	Acute Ketone Kinetics Visit (2)	Baseline Visit (3)	At Home	At Home	Interim Visit (4)	Phone Check In	Final Visit (5)
Time		Day -56 to -21	Day -42 to -7	Day 0	Days 1 to 14	Days 15 to 84	Week 4	Weeks 2, 6, 8 and 10	Week 12
SCREENING									
Demographics	X	X							
Inclusion/Exclusion	X	X	X	X			X	X	X
Interview for Frailty Measures	X	X							X
Informed Consent		X							
Review Medical History & Medication History		X		X			X	X	X
Vitals/Anthropometrics		X		X			X		X
Blood and urine sampling – safety labs		X		X			X		X
Randomization		X							
INTERVENTIONS									
Acute ketone kinetics			X						
Daily study product consumption					X	X			
ASSESSMENTS									
Capillary Blood Sampling			X						
Assess tolerability			X		X	X	X	X	X
Stool sample collection			X	X	X		X		X
Blood and urine archiving – biomarker analysis				X			X		X

Diet Recall				X					X
Physical Testing				X					X
Cognitive Testing				X					X
Study Questionnaires				X					X
Wrist actigraphy					X	X			
Continuous ketone monitor					X				
Adherence monitoring							X	X	X

Figure 1: Schedule of BIKE Study screening, interventions and assessments- SPIRIT Figure

